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Abstract Nature is interwoven with communication and is
represented and reproduced through communication acts.
The central question is how may multimodal modularly
acting and less toxic therapy approaches, defined as
modular therapies, induce an objective response or even a
continuous complete remission, although single stimulatory
or inhibitingly acting drugs neither exert mono-activity in
the respective metastatic tumor type nor are they directed to
potentially ‘tumor-specific’ targets. Modularity in the
present context is a formal pragmatic communicative
systems concept, describing the degree to which systems
objects (cells, pathways etc.) may be communicatively
separated in a virtual continuum, and recombined and
rededicated to alter validity and denotation of com-
munication processes in the tumor. Intentional knowledge,
discharging in reductionist therapies, disregards the risk-
absorbing background knowledge of the tumor’s living
world including the holistic communication processes,
which we rely on in every therapy. At first, this knowledge
constitutes the validity of informative intercellular process-
es, which is the prerequisite for therapeutic success. All
communication-relevant steps, such as intentions, under-
standings, and the appreciation of messages, may be
modulated simultaneously, even with a high grade of
specificity. Thus, modular therapy approaches including
risk-absorbing and validity-modifying background knowl-
edge may overcome reductionist idealizations. Modular
therapies show modular events assembled by the tumor’s
living world as an additional evolution-constituting dimen-
sion. This way, modular knowledge may be acquired from
the environment, either incidentally or constitutionally. The
new communicatively defined modular coherency of
environment, i.e. the tumor-associated microenvironment,
and tumor cells open novel ways for the scientific
community in ‘translational medicine’.
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Introduction
Nature is interwoven with communication and is repre-
sented and reproduced through communication acts. As
communication is a process covering all cell communities,
also those in tumor tissues, it seems to be difficult to
imagine that particularly cancer diseases originate from an
equipollent cell only. Therefore, considerations about
communication processes within the tumor compartment
have to start with the central question whether an
equipollent, communicatively structured tumor microenvi-
ronment is necessary rather than individual cells causing
specific cancer diseases.
Single molecular changes in cancer cells, as specific as
they may be, only lead to the development of specific
malignancies, when they actively communicate on a sub-
cellular level to finally alter cellular behavior and when
adjacent cell types acknowledge the communicated infor-
mation in a sense the originator intended. This communi-
cative act must allow and must be responsible for the
reorganization of well-established normal tissue. Further, in
view of the differential steps of communication, the cell
community in tumor tissue, which is represented as a
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determining the functionality (quiescent, tumor-promoting
phase) of cancer (stem) cells and the development of cancer
disease.
Consecutively, tumor development may be described as
pathological communication processes on the tissue, the
cellular, and the molecular level. Complex biochemical
networks are mediators of cellular communication and,
considering the multiplicity of tumor-associated communi-
cation processes we should include the sub-cellular com-
plexity of biochemical networks as a target into novel
concepts of therapeutic approaches.
Transcription factors with their concerted activity are
central regulators of sub-cellular communication processes.
Their complex integration into the sub-cellular context is
best characterized by their often chimera-like function,
equivalent with their communicative integration within
networks, which constitute multifold systems functions
within the tumor tissue. Dependent on distinct circum-
stances (the often unconsidered ‘background’), they may
exert cell type-dependent opposing biological effects.
Consequently, a major challenge is to elaborate how single
communication processes acquire validity and distinct
denotations on the background of numerous input signals
discharging into specific biological responses that control
tumor evolution.
Up to now, frequently used tumor therapies aim at
blocking distinct communication processes involved in
tumor promotion, for instance, by changing the denotation
of a distinct communication-associated pathway in tumor or
stroma cells or by directly targeting and eliminating the
bulk of tumor cells (monoclonal antibodies). Successful
examples of ‘magic bullets’ (Paul Ehrlich) in standard
clinical care in hematology are, for instance, tyrosine kinase
inhibitors in chronic myelocytic leukemia and monoclonal
CD20 antibodies in B-cell lymphomas [1, 2]. The under-
lying idealizations with regard to the manner of how to use
therapeutically relevant changes in denotations of ‘tumor-
specific’ pathways refer to a well-rehearsed coherency of
interactions that should fulfill practical and, at best, tumor-
specific functions. Therefore, therapeutic approaches in
tumor therapy are predominantly designed in a reductionist
way [1].
Previous modes for therapeutically modifying commu-
nication processes in metastatic tumors included, for
instance, the use of small molecules, monoclonal anti-
bodies, or cellular therapies. The modes were based on the
intentional comprehension of these communication pro-
cesses [1], presuming what distinct communicating cells
generally (i.e. under generalized conditions) insinuate with
a signal used in a given situation. This way of generalizing
validity of an addressed signal distracts from the often
situatively complex biochemical conditions that make a
signal valid in the first place. Context-related changed
validity of transcription factors and consecutively altered
denotations are exceptional examples.
The dimension validity of a communication process is
introduced by formal communication theories that are
trying to assume circumstances under which a communi-
cation process is or becomes valid. Although acknowledge-
ment of validity is a prerequisite of communication
processes, the functional and structural premises for
redeeming validity are commonly discussed to a far lesser
extent, if not neglected altogether [3–5].
The communication theory developed in this paper is
anchored in observations derived from controlled clinical
trials on the use of a combination of biomodulatory acting
drugs (= systems-directed therapies) in a broad variety of
metastatic tumors [6]. Reductionist considerations may not
explain how multimodal, less toxic systems-directed ther-
apies are able to induce an objective response, even a
continuous complete remission, although single stimulatory
or inhibitingly acting drugs (i.e. modulators of transcription
factors) do neither exert mono-activity in the respective
metastatic tumor type and nor are they directed to
potentially ‘tumor-specific’ targets [6]. As an explanation
for the activity of these biomodulatory therapy approaches,
we introduced a new communication-technically para-
phrased term as target for the cumulative functional activity
of systems-directed therapies known as tumor-specific
‘topologies of aggregated action effects’ [6]: Systems-
directed therapies may primarily neglect tumor-related
activities that seem to be operationally induced by the
division of function, such as inflammation, neoangio-
genesis, Warburg effect, immune response, extra-cellular
matrix remodeling, cell proliferation rate, apoptosis, and
coagulation effects. From a systems perspective, these
differential activities present themselves as an enhancement
of complexity [6]. Their presenting character turns out to be
primarily communicative, as shown in the methodological
discussion.
Communication-technical considerations will be helpful
to uncover mechanisms of action of modularly designed
therapy approaches and to conceptualize how this novel
way of treatment modulates sub-cellular and cellular
communication. At first, these considerations involve a
theory relating to communicative aspects of socially linked
cell communities, such as the tumor compartment. The
theory is also supported by observations derived from a
unique pattern of modular therapies administered in a broad
variety of metastatic tumors [6].
This theory leads to the question how communication
processes may be initiated (therapeutic aspect) in the
context of the basic components of the communicative
‘metabolism’, which foster natural or therapeutically
adjoined but implicitly evolutionary-linked tumor develop-
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intercellular communication processes by modular events
may be an important mechanism promoting tumor evolu-
tion or treatment.
Methods: A Formal-Pragmatic Communication Theory
Clinical results used to support the formal-pragmatic
communication theory refer to recently published data
[6].
Definition of the Tumor’s Living World as a Holistic
Communicative Unit
Exemplarily for cellular transcription factors, their context-
dependent and cell type-specific transcriptional activity
illustrates the meaning of the term modularity. The activity
is mirrored on a cellular level by the multi-functionality of,
for instance, macrophages or fibroblasts.
Modularity in the present context is a formal-pragmatic
communicative systems concept, describing the degree and
specificity to which systems’ objects (cells, pathways,
molecules, e.g. transcription factors, etc.) may be commu-
nicatively separated in a virtual continuum, reassembled
and rededicated (e.g. co-option) to alter validity and
denotation of communication processes. This concept refers
to possible interactions between the systems objects in a
tumor as well to the degree to which the communicative
rules of the systems architecture (for establishing validity
and denotation) enable or prohibit the focus on validity and
denotation. Systems objects acquire the features of sym-
bols, which are rich in content and which are able to
acquire novel references by rearranging validity and,
consecutively, denotation. Tumors consist of modules,
which become a scientific object by communicatively
uncovering the tumor’s living world (defined as the tumor’s
holistic communicative world) with biomodulatory and
therefore modularly designed events (for instance biomo-
dulatory therapies).
Modularity implicitly imparts a certain degree of evolv-
ability to systems by allowing specific modular features (i.e.
modular communicative networks) to undergo changes with
regard to validity and denotation of systems objects without
substantially altering the functionality of the entire commu-
nicative system (holism of the tumor’s living world): The
systems ‘metabolism’ modularly and non-randomly changes
validities and denotations of biochemical and biological
processes. Modularly induced evolutionary steps advance the
classic definition of evolvability as the capacity of an
organism or a biological system to generate new heritable
phenotypes [7] by evolvability within the tumor’sl i v i n g
world.
Situative Objectivation of the Tumor’s Living World
We, and the smallest living units, i.e. socially intercon-
nected cell communities, are ‘born’ to communicate. To
describe intercellular communication features, we are con-
strained to terms borrowed from appraising interpersonal
relations: Cell systems are getting instigated, educated,
reeducated, and attracted, and addressed cells may even be
subject to fallacies [8–12]. These few samples, describing
different modes of agreement by an addressee or an
addressing cell unit, show communication processes that
are more than the appreciation of signals independent of
the level of communication. Prerequisite for the follow-
i n gd i s c u s s i o ni st h a tw ea s s i g nas i n g l ec e l lc o m m u -
nication competence on the background of its genetic
repertoire.
Communication processes with their occasionally com-
plex facets of appreciation and generation of agreement
might be considered constitutive in nature. However, the
question arises whether differentially designed and thera-
peutically aligned communication procedures, such as
modular therapy approaches, have the ability to objectify
interrelations and communication structures between basi-
cally communicatively associated and evolutionary devel-
oping cell communities, such as tumors. If so, a second
and now situative objectivation could be generated besides
the intentionally acquired previous context-dependent
knowledge.
Addressing the question which background communica-
tion processes may be initiated in tumors first, for instance,
to alter the validity and denotation of transcriptional
processes, requires a clarification of the single steps of
communication from an intentional point of view (commu-
nication theory). In a second step, we have to explain the
background which principally allows the commonly used
reductionist therapy approaches to uncover the so far
frequently unconsidered risk-absorbing background
‘knowledge’. This knowledge reassures systems robustness
as illustrated by recovery from reductionist therapeutic
interventions for tumor control. Tumor’s robustness may be
specifically responsible for poor therapeutic outcome, and
robustness may absorb severe therapy-induced toxicities in
a patient’s organism.
How may the social organization of a tumor be possible?
If modular events, similar to modular therapy approaches,
tie the holistic communicative activity of a tumor, a
‚social’ action theory could be derived, which may
objectify the ‘metabolism’ of evolving evolutionary
systems. An analysis of the prerequisites for communi-
cative action seems to be necessary to exploit the
dimension of the living world’s background, which
cross-links and stabilizes larger cell communities, such
as tumors.
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of a Communication Process
A formal-pragmatic theory about the denotation of a
communication process may establish an internal interrela-
tion of denotation and validity.
Intention is inherent to all messages, also in those of
intercellular communication. The understanding of a signal
or a more complex message by the addressed cell is a
prerequisite for the requested appreciation of a message.
Appreciation is a normative notion, dominant and rich
in content, which reaches out to the understanding of, for
instance, transcriptional cascades, which may be context-
dependently assessed as a ‘grammatical’ phrase. The
understanding of a cellular signal, which has been per-
ceived as valid, is not equivalent with the appreciation of an
addressed intention (agreement, disagreement, refusal, etc.).
Signals, which are perceived as valid and valid signals
should be differentiated.
If appreciation is established, for example, in an
agreement, both sites of an intercellular communicative
exchange have to accept the respective communication
process as appropriate. Appreciation assesses the intercel-
lular acknowledgement of the validity of a basically
criticizable intercellular communication process.
Denotation issues cannot be completely separated from
validity issues. The denotation-theoretical question ‘what
does it mean to understand a communication process’
cannot be isolated from the question under which circum-
stances a communication process may be considered to be
valid.
Perception of Validity
A cell would not know what it means to understand the
denotation of a communication process, if it did not know
how to help itself to agree on something with other cells.
The prerequisites for communicative comprehension via
transmitters, ligands, cytokines, and hormones, etc. may
already appreciate that the communicative activity, which
may be established with their help, is directed to the
comprehension of a transmitted message. That means, as
long as a ‘tumor cell’ does not find a comprehensive
cellular surrounding or may not traffic suitable cell types in
its adjacent surroundings, it may not function as a tumor
cell. Therefore, also disabling comprehension within com-
munication pathways may be a therapeutic aim.
The communicative activity of many molecules and
communicative structures is context-dependent with regard
to the validity and denotation within a communication
process; for instance, single NF-kappaB signaling pathway
can perform multiple biological functions even in the same
clonal populations. This phenomenon may be assessed for
many transcriptional processes [13–17]. The communica-
tion process itself may be hedged by highly variable
cellular communication architectures (synapses, gap junc-
tions, receptors, pathways, transcription factors, acetylation
modifiers, etc.).
Novel Idealizations: Therapeutically Relevant Redemption
of Validity
A method for redeeming the therapeutic validity of
communication processes by administration of modular
therapies requires idealizations that are present in the living
world of a tumor (holistic communicative activity of a
tumor). These idealizations exclusively unfold their effec-
tiveness within tumor-associated communication processes.
Cells have access in form of explicit knowledge on the
background of their (epigenetically modified) genetic
repertoire. Thus, as our idealizations reach communication
competence, the cells’ explicit knowledge, which relies on
idealizations (theme-dependent context knowledge), and
the risk-absorbing knowledge of the tumor’s living world
(mediating robustness and systems context) compete in the
range of the background knowledge about the tumor’s
living world [18].
At first, this background knowledge about the tumor’s
living world represents scientifically none-thematized,
situative, speculative, horizon-knowledge. We implicitly
rely on this risk-absorbing knowledge in every therapeutic
intervention. The background knowledge covers the many
assumptions we silently make based on a speculative
horizon.
The background knowledge about the living world is
subjected to conditions of scientific comprehension: Inten-
tional ways fail to describe risk-absorbing knowledge, in
which context-dependent knowledge about commonly
administered reductionist therapy approaches is rooted,
and the network of the holistic communicative activities
turns out to be the medium through which the tumor’s
living world is mirrored and generated.
In an evolutionary developing tumor system, the
idealizing potency lies in the therapeutic anticipation of
physicians: Communicative actions (modular therapeutic
interventions) are now an element of a cycle process, in
which the physician is likewise a product of current
knowledge and tradition. Therefore, tumor systems biology
may not be generally interpreted in context-free explanations
[6].
Holistic character of communication Each communication-
initiated activity is linked via communication-technical
relations with many other communication-initiated activi-
ties. The knowledge about a communication technique
(modular therapy) is interwoven with the knowledge about
S230 A. Reichle, G.C. Hildebrandtthe behavior of the communicatively uncovered living
world of a tumor.
Implementation of the Formal-Pragmatic
Communication Theory
Exploitation of Background Knowledge
About The Tumor’s Living World: Disrupting
the Holistic Communicative Thicket
A formal-pragmatic communication theory is provided to
explain the therapeutic efficacy of drug combinations
characterized by exclusively combined biomodulatory
activity and no or poor mono-activity.
Clinical Results Supporting a Formal-Pragmatic
Communication Theory
If modularly designed therapies particularly target commu-
nicatively linked systems, i.e. their modularity as repre-
sented by a distinct systems response (e.g. attenuation of
inflammation), modularity should be indicated by unique
systems-associated biomarkers. Vice versa, identical mod-
ular systems should be accessible for different biomodula-
tory designed therapy approaches because of the tumor- or
situation-dependent variation of cellular promoters of
modular systems [17, 19].
As shown in Table 1, modular systems architecture of
metastatic tumors could be uncovered by a small set of
biomodulatory therapies. Differentially designed therapy
modules were able to uniquely induce a response in serum
C-reactive protein (CRP) levels of patients across a broad
variety of metastatic tumors (Fig. 1): the observed CRP
response preceded or was closely linked to clinical tumor
response (stable disease >3 months, partial remission, or
complete remission). This demonstrates that tumor-
promoting pro-inflammatory processes are differentially
accessible from a communication-technical point of view
and differentially constituted in their modularity. Never-
theless, CRP may serve as a unique modularly-linked sys-
tems marker to early show the efficacy of these therapies
[6].
Most cells within the tumor compartment are constrained
to respond to administered modular therapies: targeted
molecules are ubiquitously available and partially constitu-
tionally expressed, particularly certain receptors targeted
with their respective stimulatory ligands, such as the
glucocorticoid receptor, and peroxisome proliferator-
activated receptor alpha/gamma. Consequently, many cell
systems are included in processes, which may modify
modularity and consecutively evolvability. Clinically, this
Table 1 Therapy modules
Module A
(lead-in)
Module M Module A/M Module A/M
plus dexa
Module A/M
plus interferon-a
Melanoma*“ (randomized) + + + ––
Gastric cancer**“ (ran.) – ++ ––
RCCC**“ (sequential) ––+ – +
HRPC**‘– – – + –
Sarcoma*“ + – + ––
LCH*“– – + ––
A = pioglitazone 60 mg daily plus rofecoxib“ 25 mg daily or etoricoxib‘ 60 mg daily
M = trofosfamide* 50 mg thrice daily, or capecitabine** 1 g/m2 or 1 g absolute twice daily for 14 days every 3 weeks
Dexa = dexamethasone 0.5 or 1 mg daily
Interferon-alpha 3 or 4.5 MU thrice weekly
Fig. 1 Shaping and focusing systems’ communication: Disrupting the
holistic thicket
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which occur within a strongly delayed time frame following
biomodulatory therapies [6].
Stage-specific and tumor-specific dysregulation of
PPARgamma and COX-2 expression in tumor cells are
now well established in a broad variety of tumors [20].
Tumor-associated dysregulation of transcription factors
(modular communication-technical background) in tumor
and stroma cells may be addressed by biomodulatory
therapies, such as low-dose metronomic chemotherapy in
combination with or without transcriptional modulators
(dexamethasone, interferon-alpha, cyclooxygenase-2 inhib-
itor (PPARdelta), and pioglitazone; Table 1)[ 6].
High PPARgamma expression was shown to be repre-
sentative for the possibility to achieve modular response
(improved survival) with different therapeutic approaches
(metronomic low-dose chemotherapy plus or minus piogli-
tazone and rofecoxib) [20]. Notably, metronomic chemo-
therapy does not even directly target PPARgamma
expression, and clinical response to therapy is not linked
to inflammation control [21]: therefore, differential modular
systems may be targeted to achieve clinical response.
Therapeutic systems-directed interactions mediated by
modular therapies may basically interfere within the
horizon of living worlds of organisms constituted elsewhere
and its organs as well as with tumors. Therapeutic
specificity may be achieved by the possibility of modifying
the tumor’s holistic communication system without signif-
icant organ-related side effects, as indicated by a large
series of clinical trials [6].
Translation of Clinical Results in a Formal
Communication Theory
Translated into a formal communication theory, adminis-
tered biomodulatory therapies do not directly alter denota-
tions of distinct pathways, such as reductionist designed
‘targeted’ therapy approaches, but redeem novel validity of
modularly induced informative communication processes
embedded into the tumor’s living world. Modularity is
shown to be a specific systems feature, which may be
operationally uncovered and defined by distinct biomodu-
latory drug combinations.
At first, from a clinical point of view, the question how
validity is redeemed with biomodulatory approaches on a
molecular or cellular basis seems to be of minor impor-
tance, whereas particularly the ‘know that’, the normative
communication-linked question is therapeutically critical
because of the possibility of bringing about therapeutically
relevant yes or no statements.
With regard to the ‘know how’, direct blocking of pro-
inflammatory signaling pathways by the administered
biomodulatory therapies may be excluded as the only
explanation for the clinically observable effects. Therefore,
decisive changes in the prerequisites of validity of, for
instance, pro-inflammatory processes have to be suggested.
Changes of validity are implicitly linked with changing
denotations of communicative processes, such as the
attenuation of tumor growth.
One molecular basis could refer to the cell type-specific
combinatorially and dynamically shaped validity and
denotation of protein complexes involved in cellular
communication networks: NF-kappaB signal transduction
pathways may regulate contradictory cellular responses in
different cell types and, as recently shown, even within the
same clonal population (i.e. cell proliferation versus
differentiation and survival, immunity, and inflammation).
Controlling factors of the function of NF-kappaB signal
transduction pathways involve time, cellular conditions,
and external circumstances [17]. However, specifically the
latter are insufficiently understood, and this particular
background knowledge could be uncovered by biomodula-
tory therapies on both a cellular and a tissue level.
At this point, the quantitative and qualitative assessment
of biochemical processes in a systems context comes into
play to prove and advance the formal-pragmatic communi-
cation theory on a biochemical level. This way, computa-
tional models on the whole tumor tissue’s cell-type-specific
‘omics’ data could be rooted in direct systems biological
observations, which may be derived from modular inter-
ventions (therapy approaches). Up to now, the direct
assignment of communication-relevant validity and deno-
tation modulating biochemical processes in distinct cell
types is only fragmentarily assessable.
For therapeutical purposes, inflammation is often sym-
bolized by the classical pro-inflammatory cytokines IL-6,
IL-1, and TNFalpha, irrespectively of the cellular sources
releasing these cytokines and the cell types calling out for
response [22]. However, modular therapy approaches,
which include the risk-absorbing, validity modifying
background knowledge into the therapeutic calculus, may
overcome these reductionist idealizations as all communi-
cation relevant steps (intention, understanding, appreciation
of messages) and the differential tumor-associated pro-
moters of communication may be simultaneously modulat-
ed (Fig. 2)[ 6].
Explication of a Formal-Pragmatic Communication Theory
The claims for redeeming novel therapeutic validity are not
only directed towards therapeutic success but also tailored
on the relation of communication to the objective features
of the tumor compartment, the evolutionary developing
modularity of a tumor, as tumor-associated pro-inflammatory
processes, for example, are differentially integrated into the
modular architecture (Fig. 1).
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spaces for evolutionary developments if modular events
(therapy) are implemented. Simultaneously, the background
of the tumor-associated living worlds loses its action-
guiding function as consensus-warranting evolutionary-
driven resource. The communicative interaction structures
are now the objects of an actor (physician), who brings
about distinct reactions in tumor processes, characterized by
specification of tumor systems’ denotations via redeeming
novel validity (Fig. 1).
Objectivation of the tumors’ living world Modular thera-
pies may be the communicative medium for establishing
novel validity of communication-driven processes within
the tumor’s living world by the rearrangement of protein
complexes, altered release of mediators, etc. (Fig. 1).
Modular therapies may supplement propositional aspects
of communication, i.e. the presence of the tumor’s living
world by normative aspects, namely by therapy-derived yes
or no statements (‘know that’): Assigned to the function of
transcription factors, the changing ‘background’ may
critically determine their validity and denotation in a
situation-related manner.
Sustainability of modular therapy Besides the possibility
for redeeming novel validity (for instance inflammation
control), modular therapy approaches are characterized by
sustainability as indicated by frequently observed late
objective tumor response [6].
Communicative systems architecture The matter of validity
of intercellular communication processes may not be
considered anymore as a matter detached from the objective
relation between communication and knowledge about
cellular behavior. From a therapeutic view, the possibility
for redeeming validity marks the change from the ‘know
how’ to the ‘know that’: Knowledge about the tumor and
communicative knowledge (modular systems) are integrat-
ed into one another. Therefore, therapeutic options about
clinically relevant modular communication techniques are
linked with the knowledge of how the communicatively
accessible living world really behaves (communicative
systems architecture).
Function of modular communication The therapeutic mod-
ulation of validity is aimed at achieving novel denotations
of communication processes [17]. The dimensions’ deno-
tation and validity are internally tightly related within
communication processes. The function of modular com-
munication is to configure the coherence between validity
and denotation. Thereby, novel denotations may be thera-
peutically tailored via modulation of validity processes (e.g.
tailoring validity of pro-inflammatory processes for tumor
control). Mediators of these communication processes are
communication-related molecules, pathways, protein com-
plexes, etc., whose denotation may be situatively exchange-
able to some degree or is subject to decisive modifications
in a non-random communicative tumor systems context
embedded in the tumor’s living world.
Specificity of redeemed communicative validity Specific
conditions of compliance for redeeming validity on the site
of the tumor’s living world constitute relations between
communication technique (specified modular therapy
approaches) and distinct tumor-associated situation-
engraved systems stages. Modular therapies in different
metastatic tumor types show a high grade of specificity for
redeeming novel validity via modular therapy elements [6].
Differentially redeemed validity of modular events
(therapy approaches) represents the convergence point that
facilitates (clinically) important yes or no statements. Not
until then does the communicative situation allow a second
objectivation of the tumor by uncovering the tumor’s living
world. Modularly changing validity and denotation of
components of the tumor’s living world represent the
dimensions fostering evolutionary processes in tumor
development, for example, the link between tumor-
associated inflammation and tumor progression.
Tumors constitute a solitary world with an internal context
This solitary world is represented by highly specific topolo-
gies of aggregated action effects. As indicated by moderate
systemic toxicity profiles of the administered modular
therapies, these action effects obviously need to be clearly
separated from those appearing in a normal organ context.
Systems-related biomarkers, such as C-reactive protein
in serum or PPARgamma expression in tumor cells, may
Fig. 2 Validity of communication processes may not be considered as
a quality, which is independent of the objective relation between
communication and perception of the tumor microenvironment
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may be closely linked to clinical response after modular
therapy. Therefore, the redemption process of a novel
therapy-guided validity may be followed early in the
therapeutic process by indicators specifically associated
with functional changes in single systems features. Inter-
estingly, the validity of prognostic markers in malignant
tumors can change with the tumor stage as demonstrated for
COX-2 expression and PPARgamma expression in mela-
noma cells [20].
Tumors are integrated systems Randomized trials clearly
indicate that tumors may be described by communicatively
integrated and interwoven systems: In melanoma, both
metronomic chemotherapy and pioglitazone plus rofecoxib
independently develop clinical systems-directed activities
and even seem to act synergistically [21]: Tumor-specific
topologies of aggregated action effects may be specifically
targeted with differential modular approaches to enhance
therapeutic efficacy as tumors are composed by various
modular elements, which are drawn into inter-systemic
exchange processes (possible synergism).
The modularity of a tumor is an independent tumor
characteristic As described, the modular systems concept
does not follow the classic systems perception of functional
pathophysiology. It is exclusively communication-derived
and guided by redeeming novel validity through modular
therapy approaches. Besides histology or molecular pathol-
ogy, the modularity of a tumor is an independent tumor
characteristic [6]: Tumors are additionally represented in a
modular communicative architecture. The modular archi-
tecture of tumor-associated cell systems is directly embed-
ded in the holistic totality of the tumor’s living world.
Modular therapy approaches may be designed tumor-
specifically and stage-specifically (Table 2) The advantage
of a modular view of therapeutic interventions is the
situative reference in topologies of aggregated action
effects. The therapeutic value of the topologies of aggre-
gated action effects lies in the presentation character of
current communicative circumstances.
Evolutionary reconstruction of tumor-associated systems
Redeeming validity is tailored on the relation of modular
communication to the objective features of the tumor
compartment, the reconstructible evolutionary (modular)
systems, for example, indicated by differential impact of
pro-inflammatory processes within the tumor system [6].
Modular events (therapies) serve as a prerequisite for the
reconstruction of the tumor’s living world, in which cells
are symbolic communicative figures with─to some
degree─exchangeable references connected by modular
structures: Consecutively, communicatively derived sys-
tems may be described by rationalization processes,
deformations, and intercellular exchange [6].
‘Metabolism’ of evolution How may new systems proper-
ties emerge? The possibility for redeeming novel validity
shows the modulation of validity as an important evolu-
tionary promoter (the ‘metabolism’ of evolution). The
formal-pragmatic communication theory is able to establish
modular coherency between environmental tumor cell-
associated and microenvironment-associated communica-
tion processes as well as a modularity-based evolvability of
systems.
Reproductive structures As the most meaningful reproduc-
tive structure we commonly suggest the genetic repertoire.
Modular therapies now show that modular events, assem-
bled by the tumor’s living world, seem to present an
additional evolution-constituting dimension, which primar-
ily lies within the limits of the genetic repertoire.
Additionally, also the heritable inventory might be evolv-
able. This way, modular knowledge may be either inciden-
tally or constitutionally acquired from the environment.
Cell communities and cells constitute themselves, alter-
nating in a close modular response to informative process-
es. Therefore, modular communication is usable as an
internal systems-relevant and environmental communica-
tion mode: The evolutionary link between two different
‘worlds’ may be successfully constituted by a formal
pragmatic communication theory.
Discussion
The living world of malignant tumors creates the term
opposite to those idealizations, which originally constitute
scientific knowledge.
‘Commonly’, W. Kolch remarked, ‘we try to find out the
function of a system by disassembling it and measuring the
activity of isolated components. This approach is very
successful in characterizing the individual parts but very
limited in reconstructing the function of a system as a
Table 2 Modular therapies
• Combined transcriptional modulation
• Metronomic chemotherapy
• Epigenetically modulating drugs
• Combine therapies including biomodulatory acting drugs without or
with poor monoactivity (indication discovery)
• Combination with reductionist approaches?
• Sequential modular–reductionist therapies?
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antithesis to reductionist concepts remains fully consistent
with reductionist scientific approaches.
A holistic communication-based model termed the
tumor’s living world now opposes reductionist systems
approaches. This world is uncovered by redeeming validity
of communicative tumor processes through the implemen-
tation of modular knowledge on the cellular and external
environment (for instance for therapeutic requirements):
The tumor’s entire communicative system is subjected to
modular interventions pursuing the integration of complex
biochemical systems processes. In the first half of the 20th
century, the biologist Spemann already characterized
evolutionary systems in a communicative context: ‘Recip-
rocal interactions may play a large role, in general, in the
development of harmonious equipotential systems [24].
Modular therapies represent an alternative therapeutic
solution compared to reductionist designed approaches.
‘Systemic’ therapies in a reductionist sense are designed by
combinations of modifiers of pathways, which are more or
less tumor-specific, and their rationale is usually based on
analytics of pathway signatures [25].
In modular therapies, the communicative complexity of
tumors, i.e. the multifold divisions in functions and struc-
tures, mirrors the modularly structured totality of tumor-
specific communication processes. The present model, a
formal-pragmatic communication theory, may now explain
the therapeutic efficacy of exclusively biomodulatory acting
drug combinations (stimulatory or inhibitory acting drugs,
which do not exert mono-activity in the respective
metastatic tumor type and are not directed to potentially
‘tumor-specific’ targets) in a modularly and evolutionary
context. These findings recall the famous remark of
Dobzhansky, ‘nothing in biology makes sense except in
the light of evolution’ [26].
The important new step in our novel concept of under-
standing tumor biology and tumor evolution is the introduc-
tion of the tumor’s living world as a holistic and therefore
self-contained communication process in its idealization, in
which external, communication-guiding interferences
(modular knowledge) may be implemented to differentially
focus on the coherency of the communication-technically, all-
important dimensions validity and denotation. Now, mostly
generalizedtaggedreferencesderivedfromcontext-dependent
knowledge about single communication-mediating cells,
molecules, or pathways may be virtually neglected for
communication-technical purposes [6]. These systems
objects may be perceived as symbols in a continuum, rich
in content, whose validity and denotation may be exchange-
able but not at random.
This way, the tumor’s living world is turning into a
scientific object that becomes accessible for experimentally
or therapeutically designed modular approaches for uncov-
ering the tumor’s modularity. This modularity is defined by
a distinct communicative architecture but also by the way
how modularity has been communicatively uncovered.
Inclusion of prepositions for validity, which are present
in the living world, and the implicit interplay of validity and
denotation, which may be focused on modular events,
afford transparency, how evolutionary processes may be
first induced in the range of their molecular-genetically
defined backbone. Imposed modular acting events, such as
modularly designed therapies, may induce significant
modular response in socially linked cell systems (prerequi-
site) and may foster space for evolutionary development by
redeeming novel validity. This space may be biochemical-
ly assessable by the multiple varying biological functions
of, for example, transcription factors [17]. Following
modular events, molecular-genetic alterations might occur
additionally.
As a holistic process, the therapeutically relevant acqui-
sition of the ‘language’ of communicative intercellular
processes followed by its transformation into a hypothesis-
creating activity on the basis of clinical results (derived
from modularly designed therapy approaches) may give
hints on the ‘metabolism’ of evolutionary tumor develop-
ment. Supported by the possibility of redeeming novel
validity of communicative processes with modular events, a
possible mechanism to promote a tumor’s evolutionary
development may be simultaneously changing validities of
communicative processes mediated by the systems objects.
The procedure is closely linked to the differential develop-
ment of novel denotations of the systems objects: via
communication-relevant processes, systems objects are
acquiring novel references within the holism of the tumor’s
living world without first substantially altering the func-
tionality of the entire communicative system.
In analogy to modular therapy approaches, constitutional
and incidental modular events from the tumor microenvi-
ronment or from the macroenvironment could be critically
involved in modularly promoting tumor development or
growth. Differentially designed modular therapy approaches
should specifically meet a tumor’s living world on corre-
sponding steps of tumor development and should allow
situation-linked insights in modular architecture (compara-
tive uncovering of a tumor’s modular architectures) [27].
Commonly used context-dependent knowledge is shown
to underestimate the impact of risk absorbing prepositional
background knowledge for pragmatic therapeutic purposes.
The combination of modest changes in therapeutic design,
i.e. the introduction of biomodulatory therapies, seem to
make a major difference in the experimental efficacy of
evaluating systems on a communication level.
We may retranslate modularly induced functional
changes in tumors into intentional knowledge by compar-
atively reconstructing novel communication-linked process-
Principles of modular tumor therapy S235es on a biochemical basis to (1) prove the formal-pragmatic
communication theory by an intentional and computational
idealization [28, 29], and to (2) advance reductionist
knowledge for novel reductionist therapy approaches,
which may be used in parallel or subsequentially.
Generally, the new communicatively defined modular
coherency of the macroenvironment, i.e. the tumor-
associated microenvironment, and the tumor cells open
novel ways for the scientific community in ‘translational
medicine’.
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Glossary
Co-option Reuse of existing genetic
components, metabolic reactions, or
signaling modules in diverse
biological systems, such as tumors,
for instance, discharging in the
evolution of patterns of dysregulated
transcription factors.
Evolvability The capacity of an organism or a
biological system to generate new
heritable phenotypes. Therapeutical
modularly induced evolutionary
steps advance this definition:
Modularity may allow
retrospectively established spaces for
primarily none-heritable evolution-
ary developments, if modular events
(therapy) are implemented.
Modularity In the present context, modularity is a
formal pragmatic communicative
systems concept, describing the
degree and specificity to which
systems objects (cells, pathways, etc.)
may be communicatively separated in
a virtual continuum and recombined
and rededicated to alter the validity
and denotation of communication
processes in the tumor.
Modular
communication
(therapies)
The function is to configure the
coherence between the validity and
denotation of communication
processes. Modular therapies may
supplement prepositional aspects of
communication, i.e. the presence of
the tumor’s living world by
normative aspects, namely by
therapy-derived yes or no statements
(‘know that’).
Risk-absorbing
background
knowledge
This knowledge constitutes the
validity of informative intercellular
processes, which is the prerequisite
for therapeutic success. Background
knowledge about the tumor’s living
world is subjected to other
conditions of scientific
comprehension: Intentional ways fail
to describe risk-absorbing knowl-
edge, in which context-dependent
knowledge about commonly admin-
istered reductionist therapy
approaches is rooted. After this
second objectifying step (physicians
as operators of tumor systems), the
networkoftheholisticcommunicative
activities turns out to be the medium
through which the tumor’sl i v i n g
world is mirrored and generated.
Tumor’s living
world
The living world comprises the
tumor’s holistic communication
processes, which we rely on in every
therapy. The living world of
morphologically defined tumor cell
systems creates the term opposite to
those idealizations, which originally
constitute scientific (intentional)
knowledge. The living world is
uncovered by redeeming the validity
of communicative tumor processes
by implementing the modular
knowledge of cellular and external
environments (for instance for
therapeutic requirements). Only with
experimental or therapeutic
experiences (modular therapies) is
the tumor’s living world separated
into categories of knowledge, for
example, into modular systems.
Specific conditions of compliance
for redeeming validity constitute
relations between communication
technique (specified modular therapy
approaches) and distinct tumor-
associated situation-engraved sys-
tems stages.
S236 A. Reichle, G.C. HildebrandtReconstruction
of tumor-associated
systems
Redeeming validity is tailored on the
relation of modular communication
to the objective features of the tumor
compartment, the reconstructible
evolutionary (modular) systems.
Robustness The inherent property of a system to
maintain normal performance
despite external and internal
perturbations.
Separated or
separating ‘social’
tumor systems
The possibility for redeeming novel
validity by modular therapies is
indicative for the existence of
biologically separated or separating
‘social’ systems, i.e. in our context,
metastatic tumors: Tumors constitute
a solitary world with an internal
context.
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